Cushing's Disease: Clinical and Laboratory Response to Bromocriptine Therapy

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 1984 Dec 1

PMID 6099377

Citations 1

Authors

M O de Pinho

R C Antunes

M B Lima

C C Francalanci

S Franco

Affiliations

Soon will be listed here.

Abstract

Four patients with Cushing's disease were treated with bromocriptine, administered three times daily, in doses ranging from 7.5 to 15 mg/day, during an average period of 80 days. Daily urinary 17-hydroxycorticosteroids (17-OHCS) and 17-ketosteroids (17-KS) excretion was measured during dynamic tests and at two-week intervals. Plasma adrenocorticotropic hormone (ACTH) and cortisol levels were also assayed before and after therapy. A marked clinical and laboratory improvement was noted in two patients, in another some clinical and laboratory improvement was obtained only after bromocriptine dosage was increased to 15 mg/day. There was no effect in the fourth patient. Thus, at least for a short period of time, bromocriptine may be useful therapy for some patients with Cushing's disease.

Citing Articles

Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Ambrogio A, Cavagnini F J Endocrinol Invest. 2016; 39(9):957-65.

PMID: 27086313 PMC: 4987391. DOI: 10.1007/s40618-016-0462-4.

References

LLOYD H, MEARES J, Jacobi J . Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells. Nature. 1975; 255(5508):497-8. DOI: 10.1038/255497a0. View

Friesen H, Tolis G . The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: the Canadian cooperative study. Clin Endocrinol (Oxf). 1977; 6 Suppl:91S-99S. DOI: 10.1111/j.1365-2265.1977.tb03343.x. View

Lamberts S, DE LANGE S, Stefanko S . Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab. 1982; 54(2):286-91. DOI: 10.1210/jcem-54-2-286. View

SILBER R, Porter C . The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma. J Biol Chem. 1954; 210(2):923-32. View

GOLD E . The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med. 1979; 90(5):829-44. DOI: 10.7326/0003-4819-90-5-829. View

Spark R, Dickstein G . Bromocriptine and endocrine disorders. Ann Intern Med. 1979; 90(6):949-56. DOI: 10.7326/0003-4819-90-6-949. View

DREKTER I, HEISLER A, SCISM G, Stern S, Pearson S, McGAVACK T . The determination of urinary steroids. I. The preparation of pigment-free extracts and a simplified procedure for the estimation of total 17-ketosteroids. J Clin Endocrinol Metab. 1952; 12(1):55-65. DOI: 10.1210/jcem-12-1-55. View

Feldman J . Editorial: Cushing's disease: a hypothalamic flush?. N Engl J Med. 1975; 293(18):930-1. DOI: 10.1056/NEJM197510302931814. View

Adams E, Ashby M, Brown S, White M, Mashiter K . Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf). 1981; 15(5):479-84. DOI: 10.1111/j.1365-2265.1981.tb00691.x. View

10.

Liuzzi A, Chiodini P, Botalla L, CREMASCOLI G, Muller E, Silvestrini F . Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab. 1974; 38(5):910-2. DOI: 10.1210/jcem-38-5-910. View

11.

Kennedy A, Sheridan B, Montgomery D . ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease. Acta Endocrinol (Copenh). 1978; 89(3):461-8. DOI: 10.1530/acta.0.0890461. View

12.

Lamberts S, Timmermans H, de Jong F, BIRKENHAGER J . The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy. Clin Endocrinol (Oxf). 1977; 7(3):185-93. DOI: 10.1111/j.1365-2265.1977.tb01314.x. View

13.

Krieger D, Amorosa L, Linick F . Cyproheptadine-induced remission of Cushing's disease. N Engl J Med. 1975; 293(18):893-6. DOI: 10.1056/NEJM197510302931802. View

14.

Del Pozo E, Varga L, Wyss H, Tolis G, Friesen H, WENNER R . Clinical and hormonal response to bromocriptin (CB-154) in the galactorrhea syndromes. J Clin Endocrinol Metab. 1974; 39(1):18-26. DOI: 10.1210/jcem-39-1-18. View

15.

Wass J, Moult P, Thorner M, Dacie J, Charlesworth M, Jones A . Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet. 1979; 2(8133):66-9. DOI: 10.1016/s0140-6736(79)90120-x. View

16.

Rees L . ACTH, lipotrophin and MSH in health and disease. Clin Endocrinol Metab. 1977; 6(1):137-53. DOI: 10.1016/s0300-595x(77)80060-1. View